Results 131 to 140 of about 1,249 (168)

VIPoma

open access: yesNihon rinsho. Japanese journal of clinical medicine, 2011
Hisato, Igarashi   +3 more
core   +4 more sources

Vipoma of the Pancreas

open access: yesArchives of Internal Medicine, 1979
A patient with a vipoma of the pancreas and persistently elevated blood levels of vasoactive intestinal polypeptide (VIP) had watery diarrhea, hypokalemia, and achlorhydria (WDHA syndrome). In the untreated state, the diarrhea was never profuse. Fecal volumes ranged from 0.16 to 1.24 L/day.
Michael A. Barraclough
openaire   +2 more sources

Management of VIPoma

open access: yes, 2019
VIPomas are extremely rare tumors that secrete excessive vasoactive intestinal peptide (VIP). Symptoms include watery diarrhea, flushing, hypotension, and dehydration. Most VIPomas are sporadic but can be associated with multiple endocrine neoplasia type 1 (MEN1). Biochemical evaluation may show hypochloremic, hypokalemic metabolic acidosis.
Rachel E. Simpson, Benjamin C. James
openaire   +2 more sources

Calcitonin-Secreting VIPoma

Digestive Diseases and Sciences, 2005
Christian Jackson   +2 more
exaly   +3 more sources

VIPoma

open access: yes, 2009
Wendy Balemans   +83 more
openaire   +2 more sources

Glucagonomas, VIPomas and somatostatinomas

Clinics in Endocrinology and Metabolism, 1980
The three new endocrine pancreatic tumour syndromes dealt with in this chapter--glucagonomas, VIPomas and somatostatinomas--are not common. Nonetheless, the patients are potentially curable by tumour resection and therefore wider knowledge of the clinical picture is of considerable importance.
S R, Bloom, J M, Polak
openaire   +2 more sources

VIPomas

2011
Abstract Vasoactive intestinal polypeptide (VIP) secreting tumours are rare neuroendocrine tumours. The associated syndrome was first described by Priest and Alexander in 1957. They reported a case that they thought to be a variant of the Zollinger–Ellison syndrome—a patient with an islet cell tumour associated with diarrhoea, peptic ...
openaire   +1 more source

Home - About - Disclaimer - Privacy